Search Results

Tolmar Inc., a fully integrated pharmaceutical company, announced results from a landmark survey of more than 300 US physicians, revealing barriers to treatment with testosterone-replacement therapy among patients and physicians that, if addressed, may improve patient care.

Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ) announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets).

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®.

The FDA is gearing up for deadlines and PDUFA dates in mid-November with Seagen, Provention, Clarus and Tolmar, and Ligand and Travere.

Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced the publication of an open-label, single arm, multicenter Phase 3 study on the efficacy, safety, and pharmacokinetics of Fensolvi® (leuprolide acetate) for injectable suspension for patients with Central Precocious Puberty.

Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today affirmed the full availability of FENSOLVI® (leuprolide acetate) for injectable suspension in its six-month dose (45mg) for pediatric patients with central precocious puberty (CPP)

TOLMAR Pharmaceuticals, Inc. today announced its exclusive sponsorship of ZERO - The End of Prostate Cancer’s (ZERO) Endurance Team at the 2018 Bank of America Chicago Marathon.

Company increases manufacturing capacity of U.S.-made drug to ensure uninterrupted supply for patients undergoing treatment amid industry shortage